Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse

Journal of Neural Transmission, Supplementa

Volumn , Issue 72, 2007, Pages 165-173

  Magyar, Kalman ^a   Szatmary I ^b   Szebeni, G ^b   Lengyel, J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Chinoin Pharmaceutical and Chemical Works Ltd   (Hungary)

Author keywords

( ) Deprenyl; deprenyl metabolites; pharmacokinetics; transdermal application

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIPARKINSON AGENT; DESMETHYLSELEGILINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; COMPARATIVE STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; MOUSE; MOUSE STRAIN; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AMPHETAMINE; AMPHETAMINES; ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; METHAMPHETAMINE; MICE; MICE, INBRED STRAINS; MONOAMINE OXIDASE INHIBITORS; SELEGILINE;

EID: 38449106403     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-73574-9_21     Document Type: Article

References (33)

1. ® treatment in Parkinsons disease: a long-term study. J Neural Transm 64:113-128
2. Carillo MC, Kanai S, Nokubo M, Kitani K (1991) (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidise in the striatum of young male rats. Life Sci 48:517-521
3. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184:119-126
4. Gaal J, Szebeni Gy, Székács G, Fejér E, Wágner Ö, Szatmári I, Magyar K, Mezei M (2000) Transdermal formulations of deprenyl: guinea pig and pig models. Neurobiology 8(2):143-166
5. Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L (1999) Oral versus transdermal selegiline antidepressant-like activity in rats. Pharmacol Biochem Behav 63(3):501-506
6. Haberle D, Szöko É, Magyar K (2002) The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 9:47-51
7. Heinonen EH, Myllyla V, Sotaniemi K, Lammintausta R, Salonen JS, Anttila, M et al (1989) Pharmacokinetics and metabiolism of selegiline. Acta Neurol Scand 126:93-99
8. Knoll J (1989) The pharmacology of selegiline ((-)-deprenyl). New aspects. Acta Neurol Scand Suppl 126:83-91
9. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine Oxidases - new vistas. Adv Biochem Psychopharmacol, Vol. 5. Raven Press, New York, pp 393-408
10. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethyl-propinylamine (E-250), a new spectrum psychic energizer. Arc Int Pharmacodyn Ther 155:154-164
11. Langston JW (1980) Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology Suppl 3 40:61-66
12. Lengyel J, Magyar K, Hollosi I, Bartok T, Bathori M, Kalasz H, Furst S (1997) Urinary excretion of deprenyl metabolites. J Chromatorgr A 762 (1-2): 321-326
13. Magyar K (1993) Pharmacology of monoamine oxidase type-B inhibitors. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B: pharmacology and clinical use in neurodegenerative disorders. Birkhauser, Basel, Switzerland, pp 125-143
14. Magyar K (1994) Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl 41:167-175
15. Magyar K (1997) The role of the metabolism of (-)-deprenyl in neuroprotection. In: Teelken AW, Korf J (eds) Proc 11th ESN Meeting. Neurochemistry section 12: Neuroprotection and neurorescue: myths and mechanisms, pp 303-308
16. Magyar K, Haberle D (1999) Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology 7(2):175-190
17. Magyar K, Szende B (2000) The neuroprotective and neuronal rescue effect of (-)-deprenyl. In: Cameron RG, Feuer G (eds) Handbook experimental pharmacology, Vol. 142. Springer, Berlin Heidelberg New York Tokyo, pp 457-472
18. Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Acad Sci Hung 32(4):377-387
19. 3H in rat brain. Progress Brain Res 106:143-153
20. Magyar K, Szende B, Lengyel J, Tekes K (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-) - deprenyl research. J Neural Transm Suppl 48:29-43
21. Magyar K, Szende B, Lengyel J, Tarczali J, Szatmáry I (1998) The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl 52:109-123
22. Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szöko É (2004) Pharmacological aspects of (-)-deprenyl. Curr Med Chem 11:2017-2031
23. Olanow CW, Godbold JH, Koller W (1996) Effect of adding selegiline to levodopa in early, mild Parkinson's disease: patients taking selegiline may have received more levodopa than necessary. BMJ [Letter] 312:702-703
24. Parkinson's Study Group (1993) Efects of Tocopherol and deprenyl ont he progression of disability in early Parkinson's disease. NEJN 328:176-183
25. Patkar AA, Pae CU, Masand PS (2006) Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 11(5):363-375
26. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542-544
27. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E (1992) Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor l-deprenyl. Drugs Exptl Clin Res VIII (5):163-171
28. Schächter M, Marsden CD, Parkes JD, Jenner P, Testa B (1980) Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 43:1016-1021
29. Szöko É, Magyar K (1995) Chiral separation of deprenyl and its major metabolites using cyclodextrin-modified capillary zone electrophoresis. J Chromatogr A 709(1):157-162
30. Szöko É, Magyar K (1996) Enantiomer identification of the major metabolites of (-)-deprenyl in rat urine by capillary electrophoresis. Int J Pharmacol Adv 1(3):320-328
31. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575
32. Tatton WG, Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47 Suppl 3: S171-S183
33. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG (2000) Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 60:197-214